Purification and Expansion of Mouse Invariant Natural Killer T Cells for in vitro and in vivo Studies
February 15th, 2021
4.2K views
We describe a rapid and robust protocol to enrich invariant natural killer T (iNKT) cells from mouse spleen and expand them in vitro to suitable numbers for in vitro and in vivo studies.
Overview
This protocol enables the purification and expansion of invariant natural killer T (iNKT) cells from mouse spleen. The process allows for a 30-fold increase in cell numbers, making them suitable for both in vitro and in vivo studies.
Key Study Components
Area of Science
- Immunology
- Cell Biology
- Neuroscience
Background
- iNKT cells are rare immune cells with significant roles in immune responses.
- Purification of these cells is challenging due to their low abundance.
- Expanding iNKT cells is crucial for various research applications.
- This protocol aims to streamline the process of obtaining and expanding these cells.
Purpose of Study
- To provide a rapid and efficient method for iNKT cell purification.
- To enable significant expansion of iNKT cells for research purposes.
- To facilitate the use of iNKT cells in both in vitro and in vivo studies.
Methods Used
- Dissection of mouse spleen to obtain a single cell suspension.
- Use of a 70 nanometer cell strainer for cell purification.
- Centrifugation to isolate the cell pellet.
- Resuspension of the pellet in ammonium chloride potassium lysine buffer.
Main Results
- Successful purification of iNKT cells in one day.
- Achieved a 30-fold expansion of iNKT cells within two weeks.
- Produced a large number of ready-to-use iNKT cells for experiments.
- Demonstrated by Gloria Delfanti, a post-doc in the lab.
Conclusions
- The protocol provides a reliable method for iNKT cell enrichment.
- It significantly increases the availability of these cells for research.
- This approach can enhance studies involving immune responses.
Frequently Asked Questions
What are iNKT cells?
Invariant natural killer T (iNKT) cells are a unique subset of T cells that play a critical role in the immune system.
How long does the purification process take?
The purification process can be completed in one day.
What is the expansion factor achieved with this protocol?
The protocol allows for a 30-fold expansion of iNKT cells.
Who demonstrates the protocol?
The procedure is demonstrated by Gloria Delfanti, a post-doc in the lab.
What is the final yield of iNKT cells?
The protocol produces a large number of ready-to-use iNKT cells for research purposes.
What applications can iNKT cells be used for?
iNKT cells can be used in both in vitro and in vivo studies to investigate immune responses.
Executive Industry Relevance
This protocol addresses the critical bottleneck of rare immune cell availability in preclinical immunology research by enabling reliable purification and 30-fold expansion of mouse iNKT cells. The approach supports mechanistic de-risking in target validation for immunomodulatory therapies by providing sufficient cell numbers for functional assays and in vivo studies. It enhances predictive confidence in early discovery by facilitating the study of iNKT cell phenotypes and functions relevant to cancer, autoimmunity, and infectious disease models.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of iNKT cell activation mechanisms using anti-CD3/CD28 stimulation to de-risk immunomodulatory targets.
- Operational Value: Provides a reproducible method to obtain highly pure (95-98%) iNKT cells from transgenic mice, reducing variability in target engagement studies.
- Scientific Value: Supports phenotypic characterization of NKT1, NKT2, and NKT17 subsets via lineage-specific transcription factors (PLZF, RORγt) to clarify biological pathways.
Screening & Assay Development
- Scientific Value: Generates expanded iNKT cells with sustained effector function (IFN-γ and IL-4 secretion) suitable for reproducible in vitro assay readouts.
- Operational Value: Yields 30-fold expanded cells by day 14, enabling scalable preparation for high-throughput screening of immunomodulatory compounds.
- Scientific Value: Allows genetic manipulation of expanded iNKT cells to dissect signaling pathways and support target confirmation in immune cell-based assays.
Translational & Preclinical Research
- Scientific Value: Facilitates adoptive transfer studies in vivo to evaluate iNKT cell-mediated tumor immune surveillance and autoimmune modulation.
- Operational Value: Maintains phenotypic stability (CD4−, T80-like effector) post-expansion, ensuring consistent preclinical model performance.
- Scientific Value: Supports risk-adjusted advancement decisions by enabling mechanistic studies of iNKT cell function in disease-relevant contexts.
Pipeline & Workflow Integration
The method integrates into the discovery continuum from target validation through preclinical evaluation by providing a scalable source of functional iNKT cells for mechanistic and phenotypic analysis.
- Discovery Biology: Supports hypothesis testing of lipid antigen presentation via CD1d and TCR signaling in iNKT cell activation and function.
- Screening: Delivers standardized, expanded cell preparations with quantitative cytokine outputs (IFN-γ, IL-4) for compound screening and lead identification.
- Analytics: Enables flow cytometry-based quantification of purity, phenotype, and expansion kinetics to inform go/no-go decisions.
- Translational Research: Connects in vitro expansion to in vivo functionality through adoptive transfer, supporting preclinical continuity.
- Enterprise Reuse: Establishes a reusable platform for iNKT cell production across multiple projects in immunology and immunotherapy.
Operational & Enterprise Impact
- Scientific Value: Increases target validation confidence by enabling detailed mechanistic dissection of iNKT cell activation and effector functions.
- Operational Value: Ensures reproducibility through immunomagnetic separation and defined cytokine-driven expansion (IL-2, IL-7).
- Strategic Value: Improves capital efficiency by reducing reliance on rare primary cells and supporting higher success rates in preclinical immunomodulatory studies.
- Portfolio Impact: Enables data-driven prioritization of immunomodulatory targets based on iNKT cell-mediated mechanism validation.
Implementation Considerations
- Requires expertise in immunomagnetic cell separation and flow cytometry for purity and phenotype validation.
- Depends on access to MACS separator, LD/LS/MS columns, anti-FITC and anti-PE microbeads, and CD1d tetramers.
- Necessitates standardized cell culture conditions (RPMI, IL-2, IL-7) and sterile technique to maintain cell viability and function.
- Involves adaptation considerations when applying to non-transgenic models due to lower iNKT cell frequency.
- Limited by the need for iVα14-Jα18 transgenic mice to achieve sufficient starting cell numbers for efficient enrichment.
Biopharma FAQs
Why is immunomagnetic separation used for iNKT cell enrichment?
Immunomagnetic separation enables depletion of non-iNKT cells using anti-FITC and anti-PE microbeads after staining with CD19-FITC and H2-IAb-FITC, yielding 95-98% pure iNKT cells from transgenic mouse spleen. This approach overcomes the rarity of iNKT cells and provides a scalable input for downstream expansion.
How does anti-CD3/CD28 bead stimulation enable iNKT cell expansion?
Anti-CD3 and CD28 magnetic beads provide T-cell receptor and costimulatory signals that, when combined with IL-2 and IL-7, drive a 30-fold expansion of purified iNKT cells by day 14 of culture. This method supports robust proliferation while maintaining phenotypic stability and effector function.
What quantitative measurements confirm iNKT cell purity and expansion?
Flow cytometry using CD1d tetramer-PE staining assesses iNKT cell purity in both pre- and post-enrichment fractions, with expanded cultures showing 85-99% purity. Cell counting at each stage tracks expansion kinetics, confirming the 30-fold increase in cell numbers over two weeks.
Why are replication and phenotypic stability important for iNKT cell studies?
Replication ensures consistent effector function, as expanded iNKT cells maintain secretion of IFN-γ and IL-4 after PMA/ionomycin stimulation, confirming a stable T80-like phenotype. Phenotypic stability across passages supports reliable in vitro assays and reproducible in vivo adoptive transfer outcomes.
What statistical analysis is required to validate iNKT cell expansion data?
Validation requires comparison of cell counts pre- and post-expansion to calculate fold increase, with statistical significance assessed across replicates to confirm the 30-fold expansion is reproducible. Analysis of cytokine secretion and phenotype distribution further supports functional validation of the expanded cell population.
